Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions (Q37952805)

25 August 2017

Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions (English)

1 reference

25 August 2017

0 references

3

Martin Bonamino

1 reference

25 August 2017

Leonardo Chicaybam

1

1 reference

PubMed ID

22053970

25 August 2017

Andressa Laino Sodré

series ordinal

2

1 reference

25 August 2017

1 October 2011

1 reference

International Reviews of Immunology

25 August 2017

1 reference

25 August 2017

30

1 reference

25 August 2017

5-6

1 reference

25 August 2017

294-311

1 reference

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

25 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Identification of T-cell epitopes for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Rational development of high-affinity T-cell receptor-like antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Building better chimeric antigen receptors for adoptive T cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Targeted elimination of prostate cancer by genetically directed human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Mechanisms maintaining peripheral tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

CD28-mediated co-stimulation: a quantitative support for TCR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

The role of TNF superfamily members in T-cell function and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Novel mouse model for carcinoembryonic antigen-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Resistance of mature T cells to oncogene transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Supernatural T cells: genetic modification of T cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Genetic engineering of T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2011.595855

10.3109/08830185.2011.595855

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22053970